Abstract
Psychosis may be seen with several movement disorders. As pharmacological treatments can sometimes worsen movement disorders, psychosis in these situations can be complex for clinicians to manage. This review covers the management of psychosis in three different movement disorders: Parkinson’s disease, dementia with Lewy bodies and Huntington’s disease.
Disclosure
JH Friedman is a lecture consultant for or has received research funding from: AstraZeneca, Acadia Pharmaceuticals, Ovation Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd., Guilford Pharmaceuticals Inc., Novartis, Solvay, Sepracor Inc., Cephalon. KL Chou is a lecture consultant for or has received research funding from: Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Novartis, Boehringer Ingelheim, Solvay.